Across TCGA pan-cancer cohorts, LCE1A Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LCE1A data layer compared with 16 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LCE1A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LCE1A expression acts as an unfavorable survival marker.
HNSC are the cancer types where LCE1A Mutation most reproducibly stratifies survival.